The IC50 values in Table 1 have been improved as follows to be more specific and detailed.
Table 1In Vitro Antiviral Effect of Selected Antimalarials against SARS-CoV-2
| Drug | Cell line | IC50 (μM) | Refs |
|---|---|---|---|
| Pyronaridine | Vero | 1.1 | [3] |
| Calu-3 | 6.4 | [3] | |
| Artesunate | Vero | 53.0 | [3] |
| Calu-3 | 1.8 | [3] | |
| Hydroxychloroquine | Vero | 1.1 | [3] |
| Calu-3 | 103.0 | [3] | |
| Mefloquine-dihydroartemisinin | Vero | Between 4.1–2.5 and 2.0–1.3 | [4] |
| Desethylamodiaquine-dihydroartemisinin | Vero | Between 4.0–5.0 and 2.0–2.5 | [4] |
| Pyronaridine-dihydroartemisinin | Vero | > 0.5–1.0 | [4] |
| Lumefantrine-dihydroartemisinin | Vero | > 33.0–2.0 | [4] |
| Piperaquine-dihydroartemisinin | Vero | > 1.0–3.1 | [4] |
a IC50 values are estimated based on the 3-point dose-response data (2x/1x/0.5x expected Cmax concentrations) in [4]. The concentrations of each drug used are shown.
Article info
Publication history
Published online: January 19, 2021
Identification
Copyright
© 2020 Published by Elsevier Ltd.
ScienceDirect
Access this article on ScienceDirectLinked Article
- Repurposing Antimalarials to Tackle the COVID-19 Pandemic
Trends in ParasitologyOctober 19, 2020
- In Brief
Artemisinin-based combination therapies (ACTs) have demonstrated in vitro inhibition of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Artemisinins have also shown anti-inflammatory effects, including inhibition of interleukin-6 (IL-6) that plays a key role in the development of severe coronavirus disease 2019 (COVID-19). There is now sufficient evidence for the effectiveness of ACTs, and in particular artesunate/pyronaridine, to support clinical studies for COVID-19 infections.
- Full-Text
- In Brief
